Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & ...

Johnson & Johnson (NYSE:JNJ – Get Free Report) was the target of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 17,570,000 ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Meta ...

Johnson & Johnson (JNJ) ended the recent trading session at $143.85, demonstrating a -1.89% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily ...

Johnson and Johnson revealed lower earnings and sales numbers than expected in Q4 2022 Even before Q4 numbers were released, JNJ started falling after a slew of new stories hit the press Even ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Johnson & Johnson announced that it has entered into an exclusive licensing agreement for the global development, manufacturing and ...

A man in Maine is suing pharmeceutical giant Johnson & Johnson for $25 million over the death of his wife, claiming that use of its “dangerous and defective” talcum powder caused her death.

Immunology leader Johnson & Johnson is specifically building upon decades of innovation to research autoimmune diseases driven by autoantibodies and alloantibodies. Antibodies seek out and kill ...